Showing 463 results
-
Media Release /- Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy- AveXis…
-
Media Release /Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall survival (OS) in HR+/HER2-…
-
Media Release /-- EXPAND study data presented at ECTRIMS 2016 show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs. placebo in patients with…
-
Media Release /-- At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff-- Best ORR was 59%, with 43…
-
Media Release /New analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores…
-
Media Release /- 104 Week sub-analysis data from the Cosentyx Phase III Measure 1 study in patients with ankylosing spondylitis (AS) presented at ACR 2015(1,2)- Two-year x-ray data from observational sub-analysis…
-
Media Release /-- Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS1-- Gilenya is the first oral…
-
Media Release /Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-–C) reduction beyond six…
-
Media Release /-- Exploratory study shows clinical improvement in patients with pulmonary arterial hypertension (PAH) -- Current treatment options have limited benefit for this debilitating, rapidly progressive and…
-
Media Release /Phase III PSMAfore trial with Pluvicto® met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411; Pluvicto more than doubled median rPFS to 12.0 months per…
